Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorEmery, A.-
dc.contributor.authorKalita-de Croft, P.-
dc.contributor.authorShakya, R.-
dc.contributor.authorLim, M.-
dc.contributor.authorKalaw, E.-
dc.contributor.authorTaege, L.D.-
dc.contributor.authorMcCart Reed, A.E.-
dc.contributor.authorLakhani, S.R.-
dc.contributor.authorCallen, D.F.-
dc.contributor.authorSaunus, J.M.-
dc.identifier.citationLife Science Alliance, 2020; 3(7):1-12-
dc.description.abstractIn vitro studies have suggested proteasome inhibitors could be effective in triple-negative breast cancer (TNBC). We found that bortezomib and carfilzomib induce proteotoxic stress and apoptosis via the unfolded protein response (UPR) in TNBC cell lines, with sensitivity correlated with expression of immuno-(PSMB8/9/10) but not constitutive-(PSMB5/6/7) proteasome subunits. Equally, the transcriptomes of i-proteasome-high human TNBCs are enriched with UPR gene sets, and the genomic copy number landscape reflects positive selection pressure favoring i-proteasome activity, but in the setting of adjuvant treatment, this is actually associated with favorable prognosis. Tumor expression of PSMB8 protein (β5i) is associated with levels of MHC-I, interferon-γ-inducible proteasome activator PA28β, and the densities of stromal antigen-presenting cells and lymphocytes (TILs). Crucially, TILs were protective among TNBCs that maintain high β5i but did not stratify survival amongst β5i-low TNBCs. Moreover, β5i expression was lower in brain metastases than in patient-matched primary breast tumors (n = 34; P = 0.007), suggesting that suppression contributes to immune evasion and metastatic progression. Hence, inhibiting proteasome activity could be counterproductive in the adjuvant treatment setting because it potentiates anti-TNBC immunity.-
dc.description.statementofresponsibilityAlaknanda Adwal, Priyakshi Kalita-de Croft, Reshma Shakya, Malcolm Lim, Emarene Kalaw, Lucinda D Taege, Amy E McCart Reed, Sunil R Lakhani, David F Callen, Jodi M Saunus-
dc.publisherLife Science Alliance-
dc.rights© 2020 Adwal et al. This article is available under a Creative Commons License (Attribution 4.0 International, as described at
dc.subjectDisease Susceptibility-
dc.subjectProteasome Endopeptidase Complex-
dc.subjectEpigenesis, Genetic-
dc.subjectGene Expression Regulation, Neoplastic-
dc.subjectEnergy Metabolism-
dc.subjectDrug Resistance, Neoplasm-
dc.subjectUnfolded Protein Response-
dc.subjectDNA Copy Number Variations-
dc.subjectImmune Evasion-
dc.subjectKaplan-Meier Estimate-
dc.subjectProteasome Inhibitors-
dc.subjectTriple Negative Breast Neoplasms-
dc.titleTradeoff between metabolic i-proteasome addiction and immune evasion in triple-negative breast cancer-
dc.typeJournal article-
dc.identifier.orcidEmery, A. [0000-0001-9441-5407]-
dc.identifier.orcidCallen, D.F. [0000-0002-6189-9991]-
Appears in Collections:Aurora harvest 8
Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_127464.pdfPublished Version2.63 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.